Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis
NCT04142749 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 146
Last updated 2022-10-06
Summary
Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c pathway in liver.
Conditions
- Non-Alcoholic Fatty Liver Disease
Interventions
- DRUG
-
Oltipraz
Total 90mg, By mouth, TID
- DRUG
-
Placebos
Total 90mg, By mouth, TID
Sponsors & Collaborators
-
PharmaKing
lead INDUSTRY
Principal Investigators
-
Yun-Jun Kim, MD.PhD · Seoul Nat'l Uni. Hospital
-
Changuk Kim, MD.PhD · The Catholic University of Korea, Uijeongbu ST. Mary's Hospital
-
Gapjin Chun, MD.PhD · Gangneung Asan Medical Center
-
Taehui Lee, MD.PhD · Kunyang University Hospital
-
Byeongguk Jang, MD.PhD · Keimyung University Dongsan Medical Center
-
Yanghyeon Baek, MD.PhD · Dong-A University Hospital
-
Byeonggwan Kim, MD.PhD · Boramae Hospital
-
Yeongseok Kim, MD.PhD · Soonchunhyang University Hospital
-
Jaeyeong Chang, MD.PhD · Soonchunhyang University Hospital
-
Jaeyeong Jung, MD.PhD · Ajou University School of Medicine
-
Hyeonung Lee, MD.PhD · Yonsei University Gangnam Severance Hospital
-
Doyeong Kim, MD.PhD · Severance Hospital
-
Munyeong Kim, MD.PhD · Wonju Severance Christian Hospital
-
Junseong Lee, MD.PhD · Inje University Ilsan Baek Hospital
-
Jinu Lee, MD.PhD · Inha University Hospital
-
Hyeongjun Kim, MD.PhD · Chung-Ang University Hosptial, Chung-Ang University College of Medicine
-
Sanghun Park, MD.PhD · Hallym University Gangnam Sungsim Hospital
-
Daewon Jun, MD.PhD · Hanyang University
-
Chun Kyun Lee, MD.PhD · National Health Insurance Service Ilsan Hospital
-
Jaeyun Jung, MD.PhD · National medical center
-
Jihun Kim, MD.PhD · Korea University Guro Hospital
-
Huieon Kim, MD.PhD · Catholic University Bucheon ST. Mary's Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-11-15
- Primary Completion
- 2022-09-02
- Completion
- 2022-09-26
Countries
- South Korea
Study Locations
More Related Trials
-
Clinical Study of 12-week Trehalose Intake in Patients With Fatty Liver Disease
NCT03738358 ·Status: COMPLETED ·Phase: NA
-
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03248882 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
NCT06078722 ·Status: UNKNOWN
-
Study in Healthy Adults Evaluating PF-07202954
NCT04857437 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
NCT05281328 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
NCT02029586 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase II Clinical Trial of Chiglitazar for NASH
NCT05193916 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
NCT06739486 ·Status: NOT_YET_RECRUITING
-
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
NCT03912532 ·Status: COMPLETED ·Phase: PHASE2
-
2-Week Study In People With Nonalcoholic Fatty Liver Disease
NCT03513588 ·Status: COMPLETED ·Phase: PHASE1
-
Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy
NCT03179995 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
NCT02316717 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
NCT03890120 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
NCT04065841 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
NCT03763877 ·Status: COMPLETED ·Phase: PHASE2
-
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
NCT05483894 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
NCT03950882 ·Status: COMPLETED ·Phase: PHASE1
-
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
NCT07128797 ·Status: RECRUITING ·Phase: PHASE1
-
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
NCT01349348 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
NCT07021443 ·Status: COMPLETED
-
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
NCT06773221 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NCT05768334 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT05648214 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia
NCT04874350 ·Status: COMPLETED ·Phase: PHASE2